Advanced

Economic burden of psoriasis and potential cost offsets with biologic treatment : A swedish register analysis

Svedbom, Axel; Dalén, Johan; Mamolo, Carla; Cappelleri, Joseph C.; Mallbris, Lotus; Petersson, Ingemar F. LU and Ståhle, Mona (2016) In Acta Dermato-Venereologica 96(5). p.651-657
Abstract

Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were... (More)

Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were estimated at USD 23,293 (95% confidence interval (95% CI) 22,372−24,199). This cost was partially offset, with savings in direct costs estimated to range from USD –1,135 (95% CI –2,050 to –328) to USD –4,422 (95% CI –6,552 to –2,771), depending on assumptions. The corresponding estimates for indirect costs savings were from USD –774 (95% CI –2,019−535) to USD –1,875 (95% CI –3,650 to –188). The study suggests that psoriasis is associated with substantial costs, which may be modifiable with treatment.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biologics, Cost savings, Cost-of-illness, Psoriasis
in
Acta Dermato-Venereologica
volume
96
issue
5
pages
7 pages
publisher
Medical Journals Limited
external identifiers
  • Scopus:84973598001
ISSN
0001-5555
DOI
10.2340/00015555-2329
language
English
LU publication?
yes
id
f945bfd8-6ca5-4c5c-9ec0-4f7cc566c8b6
date added to LUP
2016-07-12 15:22:30
date last changed
2016-11-14 09:42:56
@misc{f945bfd8-6ca5-4c5c-9ec0-4f7cc566c8b6,
  abstract     = {<p>Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were estimated at USD 23,293 (95% confidence interval (95% CI) 22,372−24,199). This cost was partially offset, with savings in direct costs estimated to range from USD –1,135 (95% CI –2,050 to –328) to USD –4,422 (95% CI –6,552 to –2,771), depending on assumptions. The corresponding estimates for indirect costs savings were from USD –774 (95% CI –2,019−535) to USD –1,875 (95% CI –3,650 to –188). The study suggests that psoriasis is associated with substantial costs, which may be modifiable with treatment.</p>},
  author       = {Svedbom, Axel and Dalén, Johan and Mamolo, Carla and Cappelleri, Joseph C. and Mallbris, Lotus and Petersson, Ingemar F. and Ståhle, Mona},
  issn         = {0001-5555},
  keyword      = {Biologics,Cost savings,Cost-of-illness,Psoriasis},
  language     = {eng},
  month        = {06},
  number       = {5},
  pages        = {651--657},
  publisher    = {ARRAY(0xaef03e8)},
  series       = {Acta Dermato-Venereologica},
  title        = {Economic burden of psoriasis and potential cost offsets with biologic treatment : A swedish register analysis},
  url          = {http://dx.doi.org/10.2340/00015555-2329},
  volume       = {96},
  year         = {2016},
}